Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum effective dose of ropivacaine for ultrasound-guided sciatic nerve block in children
ChiCTR2300067788Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in Polydactyly and syndactyly, sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: 50% minimum effective dose of ropivacaine (ED50) and 90% minimum effective dose of ropivacaine (ED90). Planned start Dec 2022; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
Polydactylysyndactyly
Beyond the preview
Go deeper on ChiCTR2300067788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067788.